Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Fortis Healthcare - Balance sheet improving, valuations reasonable; upgrade to Hold - Anand Rathi

Posted On: 2013-02-13 20:21:57

Results in line with estimates. Fortis Healthcare's (Fortis) revenue grew 154.5% yoy to Rs. 15.4bn, better than our expected Rs. 14.9bn. Its reported EBITDA margin declined 380bps yoy to 9.9% (versus our estimated 10.3%) on payment of service fees to Religare Health Trust (RHT). The company reported exceptional gain of Rs. 9.7bn, pertaining to gain on dilution of stake in RHT. Adjusting for this gain, the company reported net loss of Rs. 433m.

Healthy growth across segments. Strong revenue growth was largely driven by 20% increase in revenue from India hospitals business with improved EBITDA margin of 15.8%. Domestic diagnostics business (Super Religare Laboratories) grew 12% yoy with 370bps yoy improvement in EBITDA margin to 10.3% (down ~400bps qoq). International business revenue came at Rs. 8.2bn, up 6.4% qoq. EBITDA margin in international business sustained at ~13%.

Our take. We believe that inflow of cash from dilution of stake in RHT, divestment of Dental Corp. subsidiary by Mar'13 and issue of equity shares through the IPP route would help the company strengthen its balance sheet substantially by bringing down D/E level to 0.5x by FY14e. Further, the proportion of revenue from India business would move up to 70%+ from ~50% currently post divestment of Dental Corp., which would bring focus back to India. We maintain revenue estimates, but lower PAT marginally to factor in higher service fees to RHT, which could hit EBITDA. Management focus is currently on strengthening balance sheet and no M&A is expected in near future, which is a positive in our view.

The stock is currently trading at EV/EBITDA valuations of 13.5x FY14e and 10.8x FY15e. We upgrade the stock to Hold from Sell on improving balance sheet and reasonable valuations. We also raise our target price to Rs. 118 (earlier Rs. 110), based on 14x FY14e EBITDA and Rs. 21 for stake in RHT. Risks. Delay in execution of expansion projects and integration of international operations.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views on HDFC Ltd. 4QFY2016 Results: Angel Broking
Views on Alembic Pharmaceuticals Ltd 4QFY2016 Results: Angel Broking
Rallis India - 4QFY2016 Result Update - Angel Broking
Views on United Phosphorous Ltd 4QFY2016 Results: Angel Broking
Views on Sanofi India Ltd 1QCY2016 Results: Angel Broking
Views on ICICI Bank 4QFY2016 Results: Angel Broking
Views on ACC Ltd. 1QCY2016 Results: Angel Broking
Views on HCL Technologies Ltd 3QFY2016 Results: Angel Broking
Views on Elecon Engineering Company Ltd. 4QFY2016 Results: Angel Broking
Tata Consultancy Services - 4QFY2016 Result Update - Angel Broking
Views on Sadbhav Engineering Ltd. 4QFY2016 Results: Angel Broking
Views on Yes Bank 4QFY2016 Results: Angel Broking
Views on Rallis India Ltd 4QFY2016 Results: Angel Broking
Views on Axis Bank 4QFY2016 Results: Angel Broking
Views on Mahindra Lifespace Developers Ltd. 4QFY2016 Results: Angel Broking
Centrum Indian Railways conference - Event Update - Accelerating on the right track
Infosys - 4QFY2016 Result Update - Angel Broking
Views on Ultratech Cements 4QFY2016 Results: Angel Broking
Views on TCS 4QFY2016 Results: Angel Broking
Views on LIC Housing Finance 4QFY2016 Results: Angel Broking
Views on Infosys 4QFY2016 Results: Angel Broking
Procter & Gamble Hygiene & Health Care - Quick Take - Angel Broking
FMCG - Results Preview - Volumes expected to remain subdued - Reliance Securities
Auto sales recovery in sight - CSEC Research
Auto industry ending the year on a good note - LKP Research
Maintain Buy on MBL Infrastructures - Angel Broking
BUY JK Lakshmi Cement: AnandRathi Institutional Research
BUY Ashok Leyland: AnandRathi Institutional Research
BUY Interglobe Aviation - AnandRathi Institutional Research
BUY ITD Cementation: AnandRathi Institutional Research
BUY Suven Life Sciences: AnandRathi Institutional Research
BUY Ahluwalia Contracts (India) - AnandRathi Institutional Research
BUY KNR Constructions: AnandRathi Institutional Research
Ceat Ltd 3QFY2016 Results: Angel Broking
Sun Pharmaceuticals 3QFY2016 Results: Angel Broking
HOLD HIL: AnandRathi Institutional Research
MBL Infrastructures 3QFY2016 Results: Angel Broking
Canara Bank 3QFY2016 Results: Angel Broking
BUY NRB Bearings: AnandRathi Institutional Research
Coal India (CIL) 3QFY2016 Results: Angel Broking
Ashok Leyland Ltd (ALL) 3QFY2016 Results: Angel Broking
Hero MotoCorp 3QFY2016 Results: Angel Broking
IL&FS Transportation Network (ITNL) 3QFY2016 Results: Angel Broking
Voltas 3QFY2016 Results: Angel Broking
Union Bank of India 3QFY2016 Results: Angel Broking
State Bank of India 3QFY2016 Results: Angel Broking
BUY MEP Infrastructure: AnandRathi Institutional Research
NCC 3QFY2016 Results: Angel Broking
BUY Techno Electric and Engineering: AnandRathi Institutional Research
Cipla 3QFY2016 Results: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014